NCT06798142

Brief Summary

This study aims to characterize the relationship between plasma diquat concentrations and organ damage risk.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
193

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Feb 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress87%
Feb 2022Dec 2026

Study Start

First participant enrolled

February 1, 2022

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

January 23, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 29, 2025

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

December 5, 2025

Status Verified

November 1, 2025

Enrollment Period

2.7 years

First QC Date

January 23, 2025

Last Update Submit

November 27, 2025

Conditions

Toxic EncephalopathyDiquat Poisoning

Outcome Measures

Primary Outcomes (1)

  • Survival outcome

    28 days within the index date of presentation at emergency department

Interventions

extracorporeal treatmentPROCEDURE

Extracorporeal treatments included hemoperfusion (HP) and continuous veno-venous hemodiafiltration (CVVHDF).

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with the history of acute diquat poisoning

You may qualify if:

  • history of oral exposure to diquat solution reported by patient or proxy;
  • a specimen for the diquat plasma concentration collected immediately upon admission;
  • documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans.

You may not qualify if:

  • they had ingested other toxins in addition to diquat (qualitative toxicological screening tests);
  • diquat was not detected in specimens, or plasma concentration data were unavailable;
  • patients with an exposure time (time from exposure to emergency department presentation) longer than 48 hours;
  • data on organ damage were not unavailable;
  • combined with other central nervous system injuries other than toxic encephalopathy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210008, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

plasma

MeSH Terms

Conditions

Neurotoxicity Syndromes

Interventions

Extracorporeal Membrane Oxygenation

Condition Hierarchy (Ancestors)

Nervous System DiseasesPoisoningChemically-Induced Disorders

Intervention Hierarchy (Ancestors)

Respiratory TherapyTherapeuticsExtracorporeal CirculationSurgical Procedures, Operative

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 23, 2025

First Posted

January 29, 2025

Study Start

February 1, 2022

Primary Completion

September 30, 2024

Study Completion (Estimated)

December 31, 2026

Last Updated

December 5, 2025

Record last verified: 2025-11

Locations

CN(1)